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ABSTRACT 
Roseofilum reptotaenium is a marine cyanobacteria responsible for the loss of 50% of 
corals worldwide due to Black Band Disease (BBD). Investigating the basis for secondary 
metabolite production by R. reptotaenium cultures revealed a suite of potent anti-malarial and 
anticancer compounds that likely include dolastatin 10 and monomethyl auristatin D (MMAD). 
These R. reptotaenium cultures are non-axenic (not pure monocultures) and R. reptotaenium 
appears to require the presence of several heterotrophic bacteria to survive. Scanning Election 
Microscope (SEM) images show closely associated bacteria. Preliminary metagenomic analysis 
indicates three dominant non-cyanobacterial phyla: Bacteroidetes, Planctomycetes, and 
Proteobacteri (α-proteobacteria accounted for >50% of the entire community). We are explored 
the role of these bacteria with R. reptotaenium in producing the complex of dolastatin/MMAD 
compounds, seeking to understand the chemical ecology and genetic basis by which these 
compounds are produced. The potential involvement of the dolastatin-like suite of compounds in 
Black Band Disease in corals merits further study given the destructiveness of this disease on 
corals worldwide. 
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 1 
INTRODUCTION 
Coral reefs cover about 600,000 square kilometers of the Earth’s surface (Crossland et al. 
1991), and are among the most diverse biological ecosystems in the world (Lesser et al. 2007). 
Coral reefs provide several important physical, biological, and cultural services (Cesar 2002). 
They serve as a habitat for many different marine organisms, thereby maintaining biodiversity 
(Cesar 2002). They are also a tremendous source of marine products (e.g., seafood, raw 
materials, jewelry, and medicinal compounds), which are valued at approximately $375 billion 
per year (Richardson 1998). 
Coral reef ecosystems have been degraded at an alarming rate because of the impact of 
several threats derived from human activity (e.g., over-exploitation in fishing, non-sustainable 
tourism practices, and pollution) and natural factors (e.g., tropical storms, climatic changes, and 
coral diseases) (Lesser et al. 2007). Coral diseases are considered a major cause of coral reef 
loss. A survey of coral reef diseases in Florida Keys reef in 2001 showed that the number of 
locations exhibiting coral disease increased by 80%, and the the rate of coral mortality increased 
by 60% compared to data from 1996 (Santavy et al. 2001). Black band disease (BBD) is one of 
six dominant coral diseases infecting reefs globally and contributes to 50% of the loss of corals 
by the disease (Harborne et al. 2006; Harvell et al. 2001; Peters 1984). 
Black Band Disease (BBD) is marked by dense black bands or rings that circumscribe 
regions of damaged coral tissue (Garzón et al. 2001), and has been show to be caused by the 
marine cyanobacterium Roseofilum reptotaeneum (Fig.1). BBD was first observed on stony 
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corals in the Caribbean in the 1970s (Antonius 1977), but is now found on tropical and 
subtropical coral reefs worldwide (Sutherland et al 2004). BBD is a seasonal disease, with high 
prevalence when the temperature is above 29-30°C (Richardson et al. 2014). BBD can 
progress at a rate of 0.3 - 1 cm per day, and can kill a coral colony over several months. 
 
Figure 1. R. reptotaenium (left) causes Black Band Disease (see red arrow) in corals (Scale bar 
of  R. reptotaenium filaments is 10 µm) 
According to Richardson’s hypothesis (2014), BBD is caused by the synergistic action of 
microcystin toxin produced by R. reptotaenium and hydrogen sulfide produced by sulfate 
reducing bacteria (Richardson et al. 2014). These conditions are believed to kill the symbionts 
(Symbiodinium sp.) living in corals, leading to bleaching and coral degradation. Coral bleaching 
is the phenomenon that happens when the symbiotic interaction between coral hosts and 
symbionts is disrupted; corals will lose their algae symbionts and algal photosynthetic pigments, 
then turn to white color (Correa et al. 2009). Symbiodinium is the dinoflagellate living in 
symbiosis with corals and their relatives (Pochon et al. 2006). Corals provide a safe environment 
and the necessary compounds for Symbiodinium’s photosynthetic process while Symbiodinium 
supplies photosynthetically fixed carbon (sugars, and lipids) back to corals (Correa et al. 2009; 
Kirk et al. 2005). The sea anemone Aiptasia (Fig. 2) is a genus of symbiotic cnidarian in the 
Coral reefs 
Black Band 
Disease 
Roseofilum 
reptotaenium 
+ 
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Anthozoa class, and also lives in symbiosis with Symbiodinium sp. The symbiosis relationship 
between Aiptasia and Symbiodinium sp. is similar to the relationship between corals and 
Symbiodinium sp., and Aiptasia is often used as a laboratory model to for corals, given the 
endangered nature of many corals. 
 
Figure 2. The sea anemone Aiptasia sp. isolated from Florida Keys and cultivated in the 
laboratory.  
Richardson demonstrated that R. reptotaenium cultures can cause BBD-like symptoms on 
Diploria strigosa stony coral fragments after 7 days of cultivation in the laboratory; after 28 
days, the coral skeleton completely disintegrated (Richardson et al. 2014). However, exposure of 
healthy coral fragments to microcystin at concentrations of 50-100 µM did not appear to injure 
the coral and only resulted in a decreased number of heterotrophic bacteria on the coral surface 
(Richardson et al. 2009). R. reptotaenium is a phycoerythrin (brownish-red), motile, unbranched 
filamentous cyanobacterium first classified as Oscillatoria submembranaceae (1981) and then as 
Phormidium corallyticum (1983) based on morphology. In 2009, these were re-classified as 
Pseudoscillatoria coralii based on 97% sequence similarity (Rasoulouniriana et al. 2009). 
However, Pseudoscillatoria coralii is a dark blue-green algae with phycocyanin, not 
phycoerythrin, the pigment dominant in the brownish-red algae. Taxonomic revisions in 2012 by 
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Casamatta re-classified these as Roseofilum reptotaenium and further demonstrated in the 
laboratory that R. reptotaenium was the causative agent of BBD (Casamatta et al. 2012).  A R. 
reptotaenium type strain has been deposited at the National Center for Marine Algae and 
Microbiota (NCMA) (at the Bigelow Laboratory for Ocean Sciences) and maintained as 
CCMP3313, which is the culture source for the work described in this thesis. 
R. reptotaenium grows filamentously, with filaments about 3.0-3.9 µm wide and an 
average cell length of 2.5-4.0 µm. R. reptotaenium can grow photoautotrophically or 
mixotrophically, but not heterotrophically (Richardson 2003). The R. reptotaenium cultures are 
non-axenic (i.e., not pure monocultures) and R. reptotaenium appears to require the presence of 
several heterotrophic bacteria to survive. R. reptotaenium experiences the highest growth rate on 
L1 salt water medium in comparison to ASNIII, F2, and IMK culture media (Buerger et al. 
2016). R. reptotaenium exhibits clumping behavior and grows faster in non-disturbed conditions 
than in stirred or agitated culture conditions (Richardson et al. 2014). Clumping behavior is 
believed to lead to self-shading and reduced exposure to high intensity light (Castenholz 1988).  
In 2011, it was determined through enzyme-linked immunosorbent assay (ELISA) tests 
that R. reptotaenium cultures produce the cytotoxin microcystin-LR at a concentration of 20-40 
µg g-1 biomass (Stanić et al. 2011). Microcystins (MC) are a group of cyclic heptapeptide toxins 
produced by the cyanobacterial genera Microcystis, Oscillatoria, Planktothrix, Anabaena, and 
Nostoc (Niedermeyer et al. 2012). MCs contain 80 structural variants with the general structure 
cyclo-(D-alanine1- X2-D-MeAsp3-Z4-Adda5-D-glutamate6-Mdha7), where X and Z represent two 
variable L-amino acids (Fig. 3-left) (Sheng et al. 2007). Microcystin-LR (MC-LR) is the most 
toxic variant in which the two variable L-amino acids are leucine and arginine (Fig. 3-right) 
(MacKintosh et al. 1990). Microcystin-contaminated drinking water represents a serious human 
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health risk due to the damaging liver effects of microcystins once consumed (Hooser 2000; 
MacKintosh et al. 1990; Falconer et al. 1981). Microcystins can also act as tumor promoters, 
causing liver cancer (Hooser 2000). Experimentally, it has been shown to directly damage the 
livers of rat and mice after a few minutes of exposure (Falconer et al. 1981). 
 
Figure 3. Molecular structure of Microcystins and Microcystin LR 
In 2007, studies were initiated with MC-LR to determine its potential as an anticancer 
compound on the basis of two characteristics (Monks et al. 2007). Firstly, MC-LR is only toxic 
after being absorbed into liver cells due to its poor membrane permeability (Monks et al. 2015). 
Secondly, MC-LR kills cancer cells through phosphatase inhibition, but not by inducing 
apoptosis (Monk et al. 2015). Therefore, MC-LR can work effectively against apoptosis-resistant 
cancer cell lines. The action of microcystins against cancer cells is based on the activity of 
organic anion transporting polypeptides (OATP) (Daily et al. 2010; König et al. 2006). OATP-
1B1 and OATP-1B3 are two human proteins that can mediate the transport of microcystins from 
blood to liver cells. OATP-1B1 is fairly abundant in liver tissues while OATP-1B3 is more 
widely distributed in liver cancer cells than in healthy cells (Monk et al. 2015). The selectivity 
that favors OATP-1B3 over OATP-1B1 can offer a therapeutic window for the respective 
compound (Monk et al. 2015; Monks et al. 2007; Sainis et al. 2010).   
1 
2 
3 
4 
5
 
6
 
7
 
Microcystins Microcystins LR 
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In 2012, two hundred and seven algal cultures were sent from the Bigelow 
laboratory/NCMA to the National Center of Natural Products Research (NCNPR) for bioactivity 
screenings. The preliminary data suggested that R. reptotaenium cultures might possess potent 
antimalarial activity. While promising, the materials sent (15 mL of liquid culture per algal 
strain) were not sufficient for initiating follow-up experiments. R. reptotaenium also proved very 
difficult to culture under laboratory conditions by former research groups (Bigelow and 
Richardson labs). Owing to scientists at the NCNPR not having algal culturing expertise, 
research capacity, or sufficient interest to follow-up, this collaborative effort stalled for several 
years. From the start, the Hom lab was interested in collaborating with Dr. Michael Lomas at the 
Bigelow Laboratory to better understand the chemical and microbial ecology of algae within the 
NCMA culture collection. In 2015, I started working on studying several marine algal cultures 
before focusing on R. reptotaenium, given its relatively faster cell culturing times.
 7 
METHODS 
R. reptotaenium culturing and extractions 
Erlenmeyer flasks containing 1.5 L of L1 seawater medium (Guillard et al. 1993) (see 
recipe in Appendix A) were inoculated with 0.5-gram of wet R. reptotaenium biomass. Flasks 
were covered twice by multipurpose white paper (Georgia-Pacific Consumer Products, Atlanta, 
GA) and maintained at 30°C and 27 µEm-2s-1 under a 12:12 light/dark cycle of cool-white light. 
R. reptotaenium cultures were centrifuged at 2000 g for 3 minutes to separate biomass from 
supernatant for downstream secondary metabolite extraction (Fig. 4). As described in greater 
detail below, secondary metabolites present in the supernatant and the biomass were extracted by 
ethyl acetate and methanol, respectively, and solvent-evaporated to generate “crude” extracts. 
These crude extracts were further fractionated, dried down, resuspended in dimethylsulfoxide 
(DMSO), and submitted for antimalarial and anticancer assays, and chemical characterization 
(LC-MS/MS). DNA from fragments of biomass was also isolated for metagenomic 16S rDNA 
amplicon sequencing (Fig. 4). 
Biomass extractions. 
To extract secondary metabolites from R. reptotaenium cells, 300 mg of biomass was 
transferred to a 50 mL falcon containing 30 mL of methanol, and sonicated for 5 minutes at 
400Hz using a Branson M1800 ultrasonic bath (Branson Ultrasonics, Dansbury, CT). The 
resulting methanol slurry was centrifuged at 22,000g for 3 minutes. The biomass pellet was then 
subjected to two more extractions with methanol. Methanol supernatants were pooled and 
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evaporated at 30°C for 20 minutes to generate what we refer to as “crude biomass 
extracts.” Genomic DNA was isolated from two hundred mg of fresh R. reptotaenium biomass 
from 2 week-old and 8 week-old cultures. Genomic DNA was extracted using 500 µl of phenol: 
chloroform: isoamyl alcohol (25:24:1), cleaning up by 500 µl of isopropanol, precipitated 
overnight in 200 µl of ethanol, and re-dissolved in 20 µl TE buffer. The prokaryotic composition 
of R. reptotaenium cultures was characterized using a 250-bp portion of the bacterial 16S rRNA 
gene and Illumina MiSeq sequencing as previously described (Kozich et al. 2013; Jackson et al. 
2015). Samples were pooled, spiked with 5 % PhiX (Jackson et al. 2015), and sequenced at the 
University of Mississippi Medical Center Molecular and Genomics Core Facility (courtesy of 
Dr. Colin Jackson). Raw sequences were analyzed by mothur 1.40.0 (Schloss et al. 2009, 2011). 
Sequences were aligned against the SILVA V4 16S rRNA database (Quast et al. 2013), and 
chimeras were detected using UCHIME (Edgar et al. 2011). Valid sequences were classified 
using the Greengenes 16S rRNA classification scheme (DeSantis et al. 2006), with chloroplast 
(and mitochondrial) sequence contaminants removed. Bacterial sequences were grouped into 
operational taxonomic units (OTUs) based on 97 % sequence similarity.  
  
 9 
 
Figure 4. Protocol schematic for metabolite extraction from R. reptotaenium culture (The 
information in the red box is represented in Fig.5). 
Supernatant extractions  
The cell-clarified supernatant of R. reptotaenium cultures was transferred to a 1.5 L 
separatory funnel and combined with an equal volume of ethyl acetate (EtOAc) organic solvent. 
The funnel was inverted gently ten times in order to allow the partitioning of the active 
compounds into the EtOAc organic phase. After several minutes of allowing aqueous and 
organic phases to separate, the lighter EtOAc phase (density ~ 0.902 g/cm3) was isolated to 
ensure that any trace amounts of water were removed, while the supernatant were subjected to 
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two more rounds of EtOAc extraction. EtOAc phases were combined and evaporated using a 
BUCHI rotovapor R100 rotary evaporator (BUCHI Corp., New Castle, DE) for 45 minutes at 
30°C to generate what we refer to as “crude supernatant extracts” (Fig.5). 
 
Figure 5. Protocol schematic for the generation of the crude extracts from the supernatant of the 
R. reptotaenium culture. 
Purification of crude extracts by reverse phase chromatography. 
Reverse-phase chromatography (RPC) is widely used in drug-discovery to purify potent 
compounds from crude extracts. RPC involves two parts, a non-polar hydrophobic stationary 
phase and a polar hydrophilic mobile phase. Due to the polar/non-polar chemistry of the 
mobile/stationary phases, polar compounds that do not interact with the surface of stationary 
phase are eluted first while the non-polar compounds are eluted last. The stationary phase usually 
contains a long alkyl chain, and we used a column with 18 carbons (C18); for the mobile phase, 
we used methanol (MeOH) or acetonitrile (CH3CN), with CH3CN being a slightly more polar 
solvent (Mantoura et al. 1983). 
Load  
supernatant +EtOAc 
Agitate Separate Drain 
EtOAc 
Supernatant 
Evaporate 
Rotovap machine 
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Crude extracts were dissolved in 1mL of 1:1 methanol: water and loaded onto a C18 
column in 100 mg portions, and eluted by a series of six MeOH concentrations (0%, 20%, 40%, 
60%, 80%, 100%), with a final elution using 100% acetone. These seven solvent fractions were 
individually dried by rotavap evaporation at 30°C for 5 min, dissolved in DMSO, and submitted 
for antimalarial and anticancer assays, and chemical characterization (LC-MS/MS) (Fig. 6) 
 
Figure 6. R. reptotaenium crude extracts (biomass and supernatant) were eluted by methanol 
(MeOH) at different concentration through the C18 column. 
Similarly, 100 mg crude extracts dissolved in 1mL of 1: 1 methanol: water were loaded 
onto a C18 column and eluted by a series of six CH3CN concentrations (0%, 20%, 40%, 60%, 
80%, 100%), followed by 100% Acetone. These seven purified fractions were also submitted for 
antimalarial and anticancer assays, and chemical characterization (LC-MS). 
Characterizing potent compounds in the crude extracts by LC-MS. 
Liquid chromatography-mass spectrometry (LC-MS) is an analytical chemistry technique 
that combines the physical separation capabilities of high performance liquid chromatography 
(HPLC) and the mass analysis capabilities of mass spectrometry (MS) (Pitt 2009). HPLC is a 
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technique which forces a liquid solution (mobile phase) containing potential drug compounds 
into a C18 silica column (stationary phase) by high pressure. Due to varying polarities of the 
compounds present in the solution, there are time differences in elution of the compounds. MS is 
an analytical technique which is used to elucidate the chemical structures of molecules by 
determining the mass and elemental compositions of a given sample (Dass 2007). MS ionizes the 
molecules by an electron beam or UV light to produce charged molecules (ions). These ions are 
then separated by electromagnetic fields based on their mass-to-charge ratio (Dass 2007).  
LC-MS/MS is similar to LC-MS except LC-MS/MS generates secondary MS 
fragmentations of the primary precursor ion. The advantages of MS/MS are increased sensitivity 
and the ability to provide more detailed structural information based on the sub-fragmentation 
patterns. In collaboration with Dr. Yan-Hong Wang (NCNPR), the active fractions identified in 
the antimalarial and anticancer assays were submitted for chemical characterization by LC-
MS/MS (Waters ACQUITY UPLC system coupled with Xevo G2-S ToF mass spectrometer) 
using the gradient conditions shown below (Table 1). 
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Table 1. Gradient conditions used for LC-MS/MS analysis of R. reptotaenium extracts 
Time 
Flow 
(mL/min) 
% Acetonitrile with 
0.05% formic acid (v/v) 
% Water with 
0.05% formic acid (v/v) 
0.00 0.30 30.0 70.0 
7.00 0.30 70.0 30.0 
10.00 0.30 100.0 0.0 
15.00 0.30 100.0 0.0 
 
Bacterial Community Composition of R. reptotaenium Cultures. 
Individual bacterial strains were isolated from R. reptotaenium cultures by classic 
cultivation methods. 10 mg of R. reptotaenium biomass was streaked on 1.5% agar plates made 
with L1 medium. Plates were stored at 30°C for 4 days for bacterial colonies to develop.  
Bacterial colonies were selected based on the differences of color and morphology, and then 
made clonal by continuously streaking into new agar plates for four more times (Fig. 7). Single 
clonal bacterial colonies were selected and resuspended in 15 µl of nuclease free water in 0.2 mL 
PCR tubes, heated at 98oC for 15 minutes, then centrifuged at 22,000 g for 3 minutes to pellet all 
of the cellular debris. The supernatants (13 µl) containing bacterial DNA were then transferred to 
new 0.2 mL tubes for PCR amplification.  
Bacterial 16S rRNA genes were amplified using primers 16S rRNA forward (5’ - AGA 
GTT TGA TCC TGG CTC AG - 3’) and 16S rRNA reverse (5’ - ACG GCT ACC TTG TTA 
CGA CTT - 3'). Final PCR reaction concentrations were as follows: 5 µl of 5X PCR buffer, 1 µl 
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of 10 µM forward primer, 1 µl of 10 µM reverse primer, 0.25 µl polymerase, 3 µl DNA, and 
14.75 µl nuclease-free water added to a final volume of 25 µl. PCR reactions were carried out 
with an initial denaturing step at 95oC for 2 minutes, then followed by 30 cycles of 95oC for 15 
seconds, 68oC for 15 seconds, and 72oC for 45 seconds, with a final extension step at 72oC for 5 
minutes. The PCR products were run on an agarose gel (1% agarose, 1X Lithium Acetate Borate 
Buffer, 200V, 0.2 A) for 15 minutes, along with the negative control (nuclease-free water) to 
prior verify the qualification of PCR products. PCR products were purified using a QIAquick 
PCR Purification Kit (QIAGEN Inc., Valencia, CA). The 4Peaks software was used to clean up 
the bad signal peaks, then BLAST was used to analyze sequences in order to identify the closest 
relative in GenBank based on the percentage of identity and query cover 
(https://www.ncbi.nlm.nih.gov/blast/). 
To determine the minimum medium requirements that would enable these isolated 
bacteria to grow, they were grown in three different types of media with six replicates per each 
treatment for 9 days: (1) L1, (2) L1 with 0.25% bactopeptone (HiMedia Laboratory Pvt. Ltd., 
Maharashtra-India), (3) L1 with 25 µM sucrose. Potential secondary metabolites of these 
bacteria cultures (grown in L1 with 25 µM sucrose medium) in supernatant and biomass were 
extracted by EtOAc and MeOH, respectively, as described above and submitted to antimalarial 
assays.   
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Figure 7. Protocol schematic for the identification of the roles of the bacteria community in R. 
reptotaenium culture.  
Scanning electron microscopy (SEM) of R. reptotaenium Culture Biomass. 
In scanning electron microscopy, a beam of electrons is used to image surface properties 
of a specimen at high resolutions unattainable by conventional light microscopy (~1 nm) (Wells 
1974). Biological samples must be fixed to enable high contrast imaging. 
Fixation of the samples for SEM imaging 
Two and 8 weeks old suspensions of R. reptotaenium were fixed in 4% glutaraldehyde 
buffered with 0.1M sodium phosphate (pH 7.4) for 2 hours, then rinsed in the 0.1M sodium 
phosphate buffer for 30 min. Samples were gradually dehydrated in an ethanol series (25%, 50%, 
75%, 95%) for 40 min at each gradation, followed by three 20 min washes in 100% ethanol. The 
cells were then processed in an automatic critical point dryer Leica Microsystems model EM 
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CPD300, mounted on aluminum SEM stubs, and sputter-coated with osmium. Samples were 
imaged using a JSM-7500F 5.0 kV SEM (JEOL USA, Inc., Peabody MA) at the Center for 
Advanced Microscopy in Michigan State University.
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RESULTS 
R. reptotaenium culturing  
The original 15 mL R. reptotaenium culture we obtained from Bigelow laboratory 
contained only a small white clump of R. reptotaenium biomass. At the beginning, we inoculated 
the culture into 500 mL of L1 media and maintained it at 30°C and 27 µEm-2s-1 under a 12:12 
light/dark cycle of cool-white light but without covering. Under these conditions, R. 
reptotaenium biomass did not increase nor was there any color change from white to red even 
after two months. The culture were also maintained under the light intensity equal to the intensity 
inside 2 layers of paper, 5 µEm-2s-1, which were cut off by transparency films 75% nano ceramic 
solar (Tint Depot, Houston, TX). However, the R. reptotaenium still did not increase its biomass 
or change its color. It was believed that the white paper may decrease the light intensity and 
change the light spectrum.  
When we covered the flask twice by multipurpose white paper (Georgia-Pacific 
Consumer Products, Atlanta, GA) and maintained under the same conditions as described above, 
the culture increased its biomass and started to change the color from white to red after 4 weeks. 
We also saw that some R. reptotaenium filaments start to adhere onto the walls of the culture 
flasks, forming ring patterns approximately 3 mm in diameter. (Fig. 8). 
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R. reptotaenium 
ring patterns 
 
Figure 8. Ring patterns of an undisturbed 4 week-old R. reptotaenium culture. 
Characterizing potent antimalarial/anticancer compounds in R. reptotaenium 
extracts 
Antimalarial activity of R. reptotaenium crude extracts as a function of the duration of 
culturing. 
In collaboration with Dr. Melissa Jacob’s group at the National Center for Natural 
Products Research (NCNPR), the anti-malarial potential of bioactive metabolites derived from 
the R. reptotaenium culture was evaluated in vitro on a chloroquine (CQ) -sensitive strain (P. 
falciparum D6) and a CQ-resistant strain (P. falciparum W2). P.falciparum W2 (D6) IC50 is the 
dose that inhibits 50% growth of P.falciparum W2 (D6) relative to the control. Vero cells 
(monkey kidney cells) were used as a control to estimate general toxicity of the extracted 
compounds. The selective index (SI) is the ratio between the IC50 of the control (Vero) cells 
over the IC50 of P. falciparum and for promising drug lead compounds, usually falls within the 
range of 9-11 (M. Jacob, personal communication). The R. reptotaenium extracts generally 
showed a similar inhibition response on the P. falciparum D6 and W2 strains; we will show 
representative results using the W2 strain (Figs. 9-11) (data for the D6 strain can be found in the 
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appendix (Tables 7-9). Antimalarial assays were repeated twice; as the average data were very 
similar to the values of replicates and given only two replicates, error bars are not shown. 
R. reptotaenium crude extracts were found to produce secondary metabolites with potent 
antimalarial activity. The antimalarial activity of R. reptotaenium crude extracts increased as the 
duration of culturing increased. For example, 8 week-old R. reptotaenium supernatant crude 
extracts inhibited 50% growth of P.falciparum W2 parasite with a dose of 196 ng/mL while 
~15,000 ng/mL of 2 week-old R. reptotaenium supernatant crude extract was needed for a 
similar effect (Fig. 9-left).  The biomass crude extracts at 8 weeks showed more potent 
antimalarial activity than at 2 weeks, IC50=5,500 ng/mL vs to ~17,000 ng/mL. The supernatant 
crude extracts were generally more potent than the biomass crude extracts at the same age. For 
example, the supernatant extracts at 8 weeks was 28 times more active than the biomass extracts 
at the same age (IC50 of 196 ng/mL compared to 5,500 ng/mL) (Fig. 9-left). 
The SI value increased over time, meaning that the crude extracts of older cultures were 
more active than those of the younger cultures. The SI value of supernatant crude extracts 
increased dramatically from 3 in 2 weeks to 243 in 8 weeks (Fig.9-right). The R. reptotaenium 
culture showed the best antimalarial activity in the supernatant extracts at 8 weeks (the longest 
culturing time examined), with an IC50 <196 ng/mL, and an SI value of 243 (Fig.9). We 
speculate that if we continue maintaining the culture more than 8 weeks, the antimalarial activity 
will keep increasing, although we have not tried to do it yet due to the lack of culturing capacity. 
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Figure 9. Growth inhibition (IC50) P.faciparum W2 (left) and selectivity index (SI) of inhibition 
vs. control (right) of R. reptotaenium crude extracts according to the culturing duration. 
Eight week-old R. reptotaenium crude supernatant and biomass extracts (100 mg each) 
were purified through a C18 column and eluted using different concentrations of methanol 
(MeOH) followed by acetone. The yields for each fraction (after drying) are shown in Table 2. 
These eluted fractions were then submitted for antimalarial assays.  
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Table 2. The dry-weight yield of fractions from supernatant and biomass extracts eluted using 
different concentrations of methanol. 
Fractions Supernatant extracts (mg) Biomass extracts (mg) 
Water 82.54 71.88 
20% MeOH  1.11 2.74 
40% MeOH  0.79 1.96 
60% MeOH  0.79 2.34 
80% MeOH  1.27 1.18 
100% MeOH  0.79 0.78 
100% Acetone  0.95 1.18 
Total 88.25 82.04 
 
The water, 20% MeOH, and 40% MeOH eluted fractions from the crude supernatant 
crude extracts did not show any antimalarial activity. The five active fractions were 100% 
MeOH and 100% acetone from supernatant extracts, and the 80% MeOH, 100% MeOH, 100% 
acetone fractions from the crude biomass extracts. In the supernatant extracts, the 100% acetone 
fraction was most active, with an IC50 of 0.22 ng/mL and an SI of 216 (Fig. 10); the 100% 
MeOH fraction was slightly less active, with an IC50 of 1 ng/mL and an SI of 48. However, the 
yield of these fractions were extremely small, with only 0.95 mg of the 100% acetone fraction 
and 0.79mg of the 100% MeOH fraction from 100 mg of crude extracts (Table 2). The 100% 
acetone fraction derived from the crude supernatant extract was 27 times more potent than from 
the 100% acetone fraction biomass (0.22 ng/mL compared to 6 ng/mL).  
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Figure 10. Growth inhibition (IC50) P. faciparum W2 (left) and the selectivity index (SI) of 
inhibition vs. control (right) of R. reptotaenium fractions eluted by methanol (MeOH).  
Another set of 8 week-old crude supernatant and biomass extracts (100 mg per each) 
were loaded through a C18 column and eluted using different concentrations of acetontitrile 
(CH3CN) followed by acetone. The yields of these fractions are shown in table 3. These fractions 
were then submitted for antimalarial assays.  
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Table 3. The dry-weight yield of fractions from supernatant and biomass extracts eluted using 
different concentrations of acetonitrile. 
Fractions Supernatant extracts (mg) Biomass extracts (mg) 
Water  91.3 91.3 
20% Acetonitrile  3.1 2.5 
40% Acetonitrile  0.3 0.2 
60% Acetonitrile  0.3 0.3 
80% Acetonitrile  0.1 0.1 
100% Acetonitrile  0.3 0.1 
100% Acetone  0.2 0.3 
Total 95.6 94.8 
 
The 100% acetone fractions eluted from the crude supernatant extracts were most potent, 
with an IC50 of 0.5 ng/mL and an SI of 1134 (Fig. 11), although the yield of this fraction (dry-
weight) was low at 0.2 mg over 100 mg of input extract (Table 3). The antimalarial activity was 
spread out in the three last fractions (80% methanol, 100% methanol, and 100% acetone) when 
the crude extracts were purified by MeOH. In contrast, the antimalarial activity was focused on 
the last fraction (100% acetone) when the crude extracts were purified by acetonitrile.  
 
 
  
 24 
1
10
100
1000
10000
Water 20% 
CH3CN
40% 
CH3CN
60% 
CH3CN
80% 
CH3CN
100% 
CH3CN
100% 
Acetone -
CH3CN
Lo
g 
10
 [S
I]
Fractions
Selectivity Index (SI): inhibition vs. control 
Supernatant Biomass
 
Figure 11. Growth inhibition (IC50) P. faciparum W2 (left) and the selectivity index (SI) of 
inhibition vs. control (right) of R. reptotaenium purified fractions by different concentrations of 
acetonitrile (CH3CN).  
Anticancer activity of R. reptotaenium crude extracts 
In collaboration with Dr. David Pasco of the NCNPR, we determined that 8 week old R. 
reptotaenium crude extract inhibited more than 80% of Temodar drug-resistant glioblastoma 
brain cancer cells with an IC50 of ca. 0.1 µg/mL. However, at the same concentration, this 
extract only inhibited <40% of the triple-negative breast cancer cell growth. Generally, at 
moderate to high concentrations, the R. reptotaenium crude extracts were particularly effective 
against the Temodar drug-resistant glioblastoma cell line (Fig.12) 
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Figure 12. Anticancer activity of R. reptotaenium crude extracts on Temodar-resistant 
glioblastoma (T98G; brain cancer) and triple-negative breast cancer (MDA-MB-231) cell lines. 
LC-MS of the active fractions 
One gram of the 8 week-old R. reptotaenium crude supernatant extracts (from 40 L of 
culture) were fractionated using a C18 column and eluted by different concentrations of 
methanol and acetone as described above. The two most biologically active fractions (100% 
methanol and 100% acetone) were combined for a total of 13 mg (dry weight) of what we refer 
to as “highly active extract.” 
The five active fractions eluted by methanol (supernatant-100% methanol, supernatant-
100% acetone, biomass-80% methanol, biomass-100% methanol, and biomass-100% acetone), 
two active fractions eluted by acetonitrile (supernatant-100% acetone and biomass-100% 
acetone), and the 13 mg of highly active extract were submitted for LC-MS analysis. All active 
fractions showed a similar LC elution profile within the 2-4.5 min range (Fig. 13). The 13 mg of 
the highly active extract was divided into 4 regional parts, and submitted for antimalarial assays. 
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Part 2, which contained the peaks in the 2-4.5 min region in Fig.14, was the most active part with 
an IC50 <4.9 ng/mL and SI of 120 (Table 4). 
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Figure 13. Liquid chromatography of the active fractions. From top to bottom: five active 
fractions eluted by methanol: supernatant-100% methanol, supernatant-100% acetone, biomass-
80% methanol, biomass-100% methanol, and biomass-100% acetone; two active fractions eluted 
by acetonitrile: supernatant-100% acetone and biomass-100% acetone; 13 mg of the highly 
active extract (100% methanol and 100% acetone elution from the supernatant crude extract). 
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Figure 14. Liquid-chromatography of the supernatant-acetone 100% fraction. 
Table 4. Antimalarial activities of different parts of an LC elution of 13 mg of the highly active 
extract (from 100% methanol and 100% acetone fractions of 8-week old supernatant crude 
extract).  Part 2 contains the same peaks as those seen in Fig. 13 in the 2-4 min region. 
Parts 
P. falciparum W2 IC50 
(ng/mL) 
P. falciparum W2 SI 
Part 1: 0-2.0 min >1190 1 
Part 2: 2.0-4.5 min <4.9 120 
Part 3: 4.5-9.0 min 109 >11 
Part 4: 9.0-12.0 min >1190 1 
Combination 14 >86.5 
 
Using the Table 1 LC gradient elution conditions, five compounds were repeatedly found 
in the active 2-4 min region (Table 5). The molecular weights of these compounds often differed 
by a mass of 14, which is equivalent to a methylene (CH2) group of methylene. The MS output 
of two representative compounds consistently found are shown in Fig.15. 
0-2min 2-4.5min 4.5-9.0min 9.0-12.0min 
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Figure 15. MS and MS/MS spectra of two representative compounds repeatedly found in the 
active fractions.  
 
 30 
SciFinder (Wagner 2006) was used to search known compound databases for molecules 
having the same molecular weight, molecular formula, and retention times. The compound with 
a molecular weight of 785 was identified as likely to be dolastatin 10, a known potent anticancer 
and antimalarial compound (Pettit et al. 1989). The compound with a molecular weight of 770 
was identified as likely to be monomethyl auristatin D (MMAD), a derivative of dolastatin 10 
generated by purely synthetic means today (Miyazaki et al. 1995) (Table 6). In order to verify 
our assumption, pure dolastatin 10 and MMAD were obtained as the standards, and LC-MS/MS 
co-injection experiments with these standards and the highly active extract confirmed the identity 
of dolastatin 10 (Fig. 16) and MMAD in the active fractions (Fig. 17) 
Table 5. The probable formula and putative compound name based on molecular weight and 
retention time 
Retention time 
(min) 
Molecular 
weight 
Most probable 
formula 
Putative compound 
2.75 757 C40H65N6O6S Other compound 
3.05 771 C41H67N6O6S Monomethyl auristatin 
(MMAD) 
3.33 785 C42H69N6O6S Dolastatin 10 
3.59 801 C42H69N6O7S Other compound 
3.91 815 C43H71N6O7S Other compound 
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Figure 16. The chromatogram (above) and mass-spectrometry (below) of dolastatin 10 alone, 
dolastatin 10 co-injected with the 13 mg highly active fraction, and the 13 mg highly active 
fraction alone (100% methanol and 100% acetone fractions of the supernatant crude extract) 
  
EIC (785 Da) chromatograms of the active fraction, 
dolastatin 10, and mixture of dolastatin 10 plus the 
active fraction 
MS spectra of the active fraction, dolastatin 10, and 
mixture of dolastatin 10 plus the active fraction 
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Figure 17. The chromatogram (above) and mass-spectrometry (below) of MMAD alone, 
MMAD co-injected with the 13 mg highly active fraction, and the 13 mg highly active fraction 
alone (100% methanol and 100% acetone fractions of the supernatant crude extract).  
 
EIC (771 Da) chromatograms of the active fraction, 
MMAD, and mixture of MMAD plus the active fraction 
MS spectra of the active fraction, MMAD, and mixture of 
MMAD plus the active fraction 
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With Drs. Amar Chittiboyina and Yan-Hong Wang of the NCNPR, a possible biogenesis 
diagram of dominant metabolites in the active fractions was proposed (Fig. 18). The compound 
with molecular weight of 785 was likely dolastatin 10. The compound with molecular weight of 
771 was likely MMAD. The compounds with molecular weights of 757, 801, and 815 were the 
other compounds (Table 5).  
 
Figure 18. Proposed biogenesis of dominant metabolites in active fractions 
Understanding the role of the bacteria community in R. reptotaenium culture. 
Bacterial strains isolated from an 8 week-old R. reptotaenium culture by 16S rRNA gene 
amplification. 
Thirty-four isolated bacterial colonies (obtained after repeated passage) were randomly 
selected and submitted for 16S rRNA gene amplification. The following six bacterial strains 
were identified: Labrenzia (alexandrii), Labrenzia (aggregate), Kordiimonas sp., Muricauda sp., 
Stappia sp., and Phyllobacterium sp. (Table 5). Labrenzia (alexandrii) and Muricauda sp. were 
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the two most abundant species, accounting for 29/34 colonies, while Labrenzia alexandrii was 
the least dominant species with only 6/34 colonies.  
Table 6. The bacterial identity and frequency of colonies isolated from an 8 week-old R. 
reptotaenium culture (out of 34 randomly sampled colonies). 
Bacterial strains The number of colonies (out of 34 total)  
Labrenzia alexandrii  2 
Labrenzia aggregata  10 
Kordiimonas sp. 4 
Muricauda sp. 10 
Stappia sp. 4 
Phyllobacterium sp. 4 
Total 34 
 
Labrenzia sp., Stappia sp., Koidiimonas sp, Phyllobacterium sp. belong to α-
Proteobacteria while Muricauda sp. are in the  Flavobacteria phylum. All of these bacterial 
strains are marine heterotrophic, gram-negative bacteria. Their sizes range from 0.1 to 3.0 µm, 
and are generally rod-shaped. More detailed information of the six bacterial strains can be found 
in the Appendix (Table 10). 
Growing bacterial strains in different types of media and biological activity of extracts  
The six different culturable bacteria isolated from the R. reptaenium polyculture were 
grown in three different types of media over a 9 day-period to determine the minimum medium 
in which these species could grow. The L1 media was the negative control while the L1 with 
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peptone media was the positive control. The heterotrophic bacteria did not grow in L1 media due 
to a lack of a carbon source. Fig. 19 showed that L1 containing sucrose [0.25 µM] was the 
minimum medium in which the six bacterial strains could grow after 9 days. 
 
 
Figure 19. Species isolated and identified by 16S gene sequencing from the R. reptotaenium 
polyculture (A. Labrenzia alexandrii, B. Labrenzia aggregata, C. Kordiimonas sp., D. 
Muricauda sp., E. Stappia sp. F. Phyllobacterium sp. G. 6 of the bacteria (A-F) growing 
together) were grown in 6 different types of media during 9 days.  
The supernatant and biomass extracts of the bacteria growing alone and 6 bacteria 
growing together (grown in L1 containing sucrose) did not show any antimalarial activity. The 
IC50 concentration of almost all the bacterial strains (except L. alexandrii) was >47600 ng/mL 
and the SI was 1. The IC50 of L. alexandrii supernatant extracts was >28000 ng/mL, and the SI 
was <1.7 (Table 11-appendix B). 
 
 
9 days 
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SEM images 
SEM of 8 week-old R. reptotaenium culture biomass showed several bacteria attached to 
the cell walls of the filamentous R. reptotaenium (Fig. 20a). These bacteria exhibit various 
morphologies and sizes (Fig. 20b). At least one bacterial strain secretes extracellular 
polysaccharide webby projections into R. reptotaenium cells (Fig. 20c&d). These webby 
projections may explain in part why all former attempts to isolate axenic R. reptotaenium 
cultures have been unsuccessful. Strong antibiotic treatments and physical attempts (micropipette 
isolation) to separate the cell-wall-associated bacteria may significantly damage the 
cyanobacterial cells (Casamatta et al. 2012). 
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Figure 20. SEM images of biomass samples of 8 week-old R. reptotaenium culture. (a) R. 
reptotaenium filaments with several associated bacteria on their cell walls (4,000X); (b) 
bacterium (red arrow) attached on R. reptotaenium filament (20,000X); (c, d) bacteria attached to 
R. reptotaenium filaments via extracellular polysaccharide webby projections (red arrows) 
(40,000X and 50,000X). 
Metagenomics (16S) amplicon sequencing results showed that in addition to 
Cyanobacteria, there are dominant bacteria in the culture from the phyla of Bacteroidetes, 
a 
c d 
b 
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Planctomycetes, and Proteobacteria, with 50% of the community composition being from the (α-
Proteobacteria subphylum (Fig. 21).  
 
 
Figure 21. The relative abundance of four most dominant bacterial phyla in R. reptotaenium 8 
weeks-old culture.  
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DISCUSSION 
The antimalarial activity of R. reptotaenium extracts 
Overall, the R. reptotaenium supernatant extracts showed more potent antimalarial 
activity than the biomass extracts. For example, the antimalarial activity of the 8 week-old 
supernatant crude extracts was 28 times more potent than the biomass crude extracts of the same 
age (IC50 196 ng/ml to IC50 5500 ng/mL) (Fig. 8). In addition, the supernatant-100% acetone 
fraction eluted by methanol was 27 times more active than the biomass-100% acetone fraction 
eluted by the same solvent (IC50 0.22ng/mL to a ratio of IC50 6 ng/mL) (Fig. 9). The 
supernatant-100% acetone fraction eluted by acetonitrile was 38 times more active than the 
biomass-100% acetone fraction eluted by the same solvent (IC50 0.5ng/mL to a ratio of IC50 19 
ng/mL) (Fig. 10). It is not readily apparent why the antimalarial activity of the supernatants 
always outperformed the biomass in the antimalarial assays. We speculate that the underlying 
reason is possibly due to dolastatin 10 and MMAD being extracellular compounds, not 
intracellular compounds, meaning that R. reptotaenium polycultures can readily excrete these 
compounds into their environment. This may also explain why former attempts to isolate 
dolastatin 10 from the biomass of sea hare Dolabella auricularia (Pettit et al. 1987, 1993) and 
the biomass of the marine cyanobacteria Symploca sp. VP642 (Luesch et al. 2001) produced 
substantially smaller yields, at 10-7 % and ~10-2 % dry weight yields, respectively (Pettit et al. 
1987, 1993, Luesch et al. 2001). These extremely small yields contributed to the 15 year process 
of completely elucidating the chemical structure of dolastatin 10. Dolastatin 10 and MMAD are 
 40 
two well-known microtubule inhibitors, that can act against various cancer cells with 
picomolar concentration. 
The 100% acetone fraction eluted by MeOH and the 100% acetone fraction eluted by 
acetonitrile (CH3CN) were more active than antimalarial drugs currently on the market. The 
100% acetone fraction eluted by methanol was the most active fraction, inhibiting 50% growth 
of P. falciparum parasites at a concentration of 0.22 ng/mL, in contrast to 5.37 ng/mL of 
Artemisinin or 7.92 ng/mL of Chloroquine (Fig.22- left). The 100% acetone fraction eluted by 
acetonitrile had the highest SI value at 1134 (Fig. 22- right). 
  
Figure 22. Growth inhibition (IC50) P. faciparum W2 (left) and Selective specificity of 
inhibition vs. control (right) of R. reptotaenium extracts compared to the current antimalarial 
medicines on the market.  
The role of culture duration and the R. reptotaenium associated bacterial community 
in producing dolastatin 10 
In the process of isolating and culturing the bacteria associated with R. reptotaenium 
cultures, the colonies with distinctive colors and morphologies were sequenced by 16S rRNA 
gene amplification and identified as six different bacterial strains (Table 6). Five of the six 
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bacteria identified through this method belonged to the α-Proteobacteria subphylum, with the 
sixth bacterial strain belonging to the Flavobacteria subphylum (Table 6). This single colony 
sequencing data was generally similar to the whole genome metagenomic sequencing data, in 
which the α-Proteobacteria subphylum accounted for 53%, while the Flavobacteria subphylum 
accounted 2% relative abundance over the whole community (Fig. 20). However, no bacterial 
strains in Bacteroidetes and Planctomycetes were found by using the single colony sequencing 
method, although these phyla accounted for a large percentage of relative abundance, 13.2% and 
12.7%, respectively, in the whole genome metagenomic sequencing data (Fig. 20). 
Unfortunately, the SEM images could not be used alone to identify the bacterial strains, although 
parallel in-situ FISH probes targeting species-specific gene sequences might be able to be used 
with TEM for accurate bacterial strain identification. The secondary metabolites of the 
heterotrophic bacteria isolated from R. reptotaenium cultures did not show antimalarial activity. 
More bacterial isolation should be done to verify whether the bacterial strains in these subphyla 
were unculturable or not yet identified, and whether they show any bioactivity. The roles that the 
bacterial strains played in producing the suit of dolastatin-like complex of compounds were 
inconclusive. However, we have shown strong evidence that dolastatin 10 and its synthetic 
analogue MMAD are produced through a novel source, the marine cyanobacteria R. 
reptotaenium. At this point, we speculate that the bacteria could be adding a methylene group 
(CH2) into MMAD to produce dolastatin 10, or be removing a CH2 group from dolastatin 10 to 
generate MMAD (Fig. 23). 
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Figure 23. Monomethyl auristatin D (MMAD) was modified from dolastatin 10 
Other analogues of dolastatin 10 (Lyngbyastatin 1 and 4, dolastatin 12 and 13) were 
isolated from the marine cyanobacteria Lyngbya sp. (Harrigan et al. 1998; Matthew et al. 2007). 
Not surprisingly, R. reptotaenium belongs to the same Oscillatoriales order as Symploca sp., and 
Lyngbya sp. The Lyngbya sp. and Symploca sp. samples used to extract dolastatin 10 and its 
analogues were collected from the field, therefore, it is likely that these cyanobacteria were also 
impure, with some marine bacteria living in association with the cyanobacteria. R. reptotaenium 
comprised the polyculture in the current study, while also containing some heterotrophic bacteria 
living in association with the cyanobacteria. Presently, it is still unknown if dolastatin 10 is 
synthesized by only the cyanobacteria or by the interaction between the cyanobacteria and its 
associated bacteria. It is evident however that dolastatin 10 and MMAD increased in 
concentration as the R. reptotaenium cultures aged. We are unsure of whether the compounds 
simply accumulate over time, or whether the bacterial community shifted, causing more 
compounds to be synthesized. Evidently more research is needed to better understand the 
chemical ecology and genetic basis by which dolastatin 10 and MMAD compounds are produced 
in the context of this microbial community. 
R. reptotaenium and Black Band Disease 
 According to Richardson’s hypothesis (2014), BBD was caused by the synergistic 
impacts of microcystin-LR toxin produced by R. reptotaenium and sulfide produced by sulfate 
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reducing bacteria (Richardson et al. 2014). R. reptotaenium could produce microcystin-LR with 
a concentration of 0.02 - 0.04 mg g-1 determined by using the enzyme-linked immunosorbent 
assay (ELISA) test (Stanić et al. 2011). However, in the process of isolating dolastatin 10 and 
MMAD from R. reptotaenium polycultures, we did not see any compound with a molecular 
weight of 995 - microcystin LR. The Richardson group did use the high-performance liquid 
chromatography (HPLC) to isolate the microcystin-LR peak and compared it to the standard. 
However, the microcystin-LR yield was reported based on the results of an ELISA test. We still 
do not know whether the R. reptotaenium polycultures shift compositionally over time, and cease 
production of MC-LR, or as in the case of Richardson (2014) whether the antibodies in the 
ELISA test kit simply showed cross-reactivity with compounds other than microcystin-LR. It is 
still inconclusive as to whether microcystin-LR is the main cause of BBD or whether the 
cytotoxicity of the suit of dolastatin-like complex of compounds induces coral fatality. Lastly, 
the potential for the dolastatin-like complex to induce Black Band Disease in corals should be 
also carefully studied, given the destructiveness of this disease on corals worldwide. 
What is dolastatin 10 and MMAD? 
Dolastatin 10 and MMAD are two well-known microtubule inhibitors with important 
medical applications. Dolastatin 10 can act against various cancer cells by inhibiting microtubule 
assembly, then inducing cell cycle arrest and apoptosis. Dolastatin 10 has also shown potent 
antimalarial activity by inhibiting 50% of P.falciparum with only 10-10 M (Fennell et al. 2003). 
Despite the promising preclinical data, the phase II trial of dolastatin 10 was not successful and 
further clinical trials of dolastatin 10 are not recommended, due to its significant toxicity at the 
maximum tolerated dose (von Mehren et al. 2004; Perez et al. 2005). MMAD had a clinical 
application as a playload in antibody-drug conjugates (ADCs) (Senter and Sievers 2012) despite 
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slightly less potency than dolastatin 10 (Miyazaki et al. 1995). ADCs, an important class of 
potent biopharmaceutical drugs, are designed to kill only cancer cells and leave healthy cells 
undamaged (Bakhtiar 2016). ADCs contain 3 parts: a monoclonal antibody, a linker, and a 
playload (a cytotoxic anticancer compound) (Zolot, Basu, and Million 2013). MMAD can be 
attached to a linker and subsequently conjugated to monoclonal antibodies because it has a 
secondary amine at the N-terminus, a chemical characteristic dolastatins 10 do not have 
(Maderna et al. 2014; Senter and Sievers 2012). After being released into the cancer cells, 
MMAD will inhibit microtubule assembly, subsequently inducing cell apoptosis.  
 Dolastatin 10 and MMAD are still very expensive on the current pharmaceutical market. 
Respectively, dolastatin 10 and MMAD cost approximately $900 and $500 per mg. Further 
research can potentially focus on producing R. reptotaenium cultures able to synthesize 
dolastatin 10 and MMAD in a shorter amount of time. Such research may lead to increased 
yields of dolastatin 10 and MMAD. Finally, more experiments should be conducted to determine 
the genetic or biological pathways of dolastatin 10 and the dolastatin-like complex of 
compounds. Once such principles are uncovered, dolastatin may be produced on an industrial 
scale at a far cheaper market price by cloning the gene into E-coli. 
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L1 Medium 
Guillard and Hargraves (1993) 
This enriched seawater medium is based upon f/2 medium (Guillard and Ryther 1962) 
but has additional trace metals. It is a general-purpose marine medium for growing coastal algae.  
To prepare, begin with 950 mL of filtered natural seawater. Add the quantity of each 
component as indicated below, and then bring the final volume to 1 liter using filtered natural 
seawater. The trace element solution and vitamin solutions are given below. Autoclave. Final pH 
should be 8.0 to 8.2 
Component Stock Solution Quantity Molar Concentration in 
Final Medium 
NaNO3 75.00 g L-1 dH2O 1 mL 8.82 x 10-4 M 
NaH2PO4 ⋅ H2O 5.00 g L
-1 dH2O 1 mL 3.62 x 10-5 M 
Na2SiO3 ⋅ 9H2O 30.00 g L
-1 dH2O 1 mL 1.06 x 10-4 M 
Trace element solution (see recipe below) 1 mL --- 
Vitamin solution (see recipe below) 0.5 mL --- 
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L1 Trace Element Solution 
To 950 mL dH2O add the following components and bring final volume to 1 liter with dH2O. 
Autoclave. 
Component Stock Solution Quantity Molar Concentration 
in Final Medium 
Na2EDTA ⋅ 2H2O --- 4.36 g 1.17 x 10
-5 M 
FeCl3 ⋅ 6H2O --- 3.15 g 1.17 x 10
5 M 
MnCl2 ⋅ 4H2O 178.10 g L
-1 dH2O 1 mL 9.09 x 10-7 M 
ZnSO4 ⋅ 7H2O 23.00 g L
-1 dH2O 1 mL 8.00 x 108 M 
CoCl2 ⋅ 6H2O 11.90 g L
-1 dH2O 1 mL 5.00 x 10-8 M 
CuSO4 ⋅ 6H2O 2.50 g L
-1 dH2O 1 mL 1.00 x 108 M 
Na2MoO4 ⋅ 2H2O 19.90 g L
-1 dH2O 1 mL 8.22 x 10-8 M 
H2SeO3 1.29 g L-1 dH2O 1 mL 1.00 x 10-8 M 
NiSO4 ⋅ 6H2O 2.63 g L
-1 dH2O 1 mL 1.00 x 10-8 M 
Na3VO4 1.84 g L-1 dH2O 1 mL 1.00 x 10-8 M 
K2CrO4 1.94 g L-1 dH2O 1 mL 1.00 x 10-8 M 
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f/2 Vitamin Solution 
(Guillard and Ryther 1962, Guillard 1975) 
First, prepare primary stock solutions. To prepare final vitamin solution, begin with 950 mL of 
dH2O, dissolve the thiamine, add the amounts of the primary stocks as indicated in the quantity 
column below, and bring final volume to 1 liter with dH2O. At the NCMA we autoclave to 
sterilize. Store in refrigerator or freezer 
 
Component Primary Stock 
Solution 
Quantity Molar Concentration in 
Final Medium 
Thiamine ⋅HCl (vit. B1) --- 200 mg 2.96 x 10
-7 M 
Biotin (vit. H) 0.1 g L-1 dH2O 10 mL 2.05 x 10-9 M 
Cyanocobalamin (vit. B12) 1.0 g L-1 dH2O 1 mL 3.69 x 10-10 M 
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Table 7. Antimalarial activities of R. reptotaenium supernatant and biomass crude extracts as a 
function of culture duration. The antimalarial potential of bioactive metabolites was evaluated in 
vitro on a CQ-sensitive strain (P. falciparum D6) and a CQ-resistant strain (P. falciparum W2). 
Vero cells (monkey kidney cells) were used to estimate the toxicity of bioactive metabolites. W2 
strain generally shows the same response; exceptions are indicated by parentheses (). 
Type of  
extracts 
Length of culturing 
P. falciparum D6 
(W2) IC50 (ng/mL) 
VERO 
IC50 
P. falciparum D6 
(W2)  SI  
Supernatant  
crude  
extracts 
2 weeks 19700 (15060) >47600 >2 (>3) 
3 weeks 1100 (600) 4210 4 (7) 
4 weeks 1160 (970) >4760 >4 (>5) 
5 weeks 4030 (3090) >47600 >12 (>15) 
6 weeks <196 26780 137 
8 weeks <196 >47600 >243 
Biomass  
crude  
extracts 
2 weeks 27900 (17100) >47600 >1.7 (>2.8) 
3 weeks 5300 >47600 >9 
4 weeks 5300 >47600 >9 
5 weeks 7700 (6500) >47600 >6 (>7)  
6 weeks 2500 (4800) >47600 >19 (>9.9)  
8 weeks 3150 (5500) >47600 >15 (>8.7) 
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Table 8. Antimalarial activities of R. reptotaenium supernatant and biomass extracts purified by 
different concentrations of methanol (MeOH) followed by acetone.  
Types of 
extracts 
Purified  
fraction 
P. falciparum D6 (W2) 
IC50 
(ng/mL) 
VERO IC50 
(ng/mL) 
P. falciparum 
 D6 (W2) SI 
Supernatant 
extract 
Water NA 4760 NA 
20% MeOH NA 4760 NA 
40% MeOH NA 4760 NA 
60% MeOH 3630 (2290) 4760 >1.3 (>2.1) 
80% MeOH 710 (523) 4760 >7 (>9) 
100% MeOH 1.6 (1) 47.6 >30 (>48) 
100% 
Acetone 
0.33 (0.22) 47.6 >144 (>216) 
Biomass 
extract 
Water 114 (325) 4760 >42 (15) 
20% MeOH  114 (325) 4760 >42 (15) 
40% MeOH  4420 (3140) 4760 >1.1 (>1.5) 
60% MeOH  328 (220) 4760 >15 (>22) 
80% MeOH  17 (13) 476 >28 (>37) 
100% MeOH  2 (2) 47.6 >24 (>24) 
100% 
Acetone  
15 (6) 476 >32 (>79) 
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Table 9. Antimalarial activities of R. reptotaenium supernatant and biomass extracts purified by 
different concentrations of acetonitrile followed by acetone 
Types of  
extracts 
Purified fractions 
P. falciparum D6 (W2) 
IC50 
(ng/mL) 
VERO IC50 
(ng/mL) 
P. falciparum 
D6 (W2) SI 
Supernatant 
extract 
Water  >23800 >23800 1 
20% Acetonitrile  >36890 >36890 1 
40% Acetonitrile  >3570 >3570 1 
60% Acetonitrile  3000 (2160) >3570 >1.2 (>1.7) 
80% Acetonitrile  480 (412) >1190 >2.5 (>2.9) 
100% Acetonitrile  2960 (2380) >3570 >1.2 (>1.5) 
100% Acetone  0.6 (0.5) 567 945 (1134) 
Biomass  
extracts 
Water  543 (690) >23800 >43.8 (>34.5) 
20% Acetonitrile  11400 (1670) >29750 >2.6 (>17.9 
40% Acetonitrile  >2380 >2380 1 
60% Acetonitrile  2960 (1862) >3570 >1.2 (1.9) 
80% Acetonitrile  586 (136) >1190 >2 (>8.7) 
100% Acetonitrile  1097 (180) >1190 >1.1 (>6.6) 
100% Acetone  10 (19) >357 >35.7 (>18.6) 
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Table 10. Bacteria strains isolated from R. reptotaenium cultures. 
Labrenzia alexandrii Alphaproteobacteria; Gram (-); Size: 0.5-0.7 x 0.9-3.0µm; rod 
shape; slightly pink colony; aerobic anoxygenic phototrophs ; 
salinity: 1-10% NaCl; Biotin and thiamine are required as growth 
factors; Isolated from cultured cells of the marine dinoflagellate 
Alexandrrium lusitanicum 
Labrenzia aggregata Alphaproteobacteria; Gram (-); 1.9 um x 0.8 um; rod shape; white to 
cream colony; obligate aerobic; salinity: 0.3-6%; not require vitamin 
to grow 
Stappia indica Alphaproteobacteria; Gram (-); 1.0 um x 1.0 um; rod shape; white 
colony; obligate aerobic; salinity 0.5-11% NaCl; not require vitamin 
to grow 
Koidiimonas 
gwangyangensis 
Alphaproteobacteria; Gram (-); 1.3–1.4 mm x 0.25 mm; rod shape; 
translucent, creamy white colony; obligate aerobic; optimal NaCl  
2%; isolated from Korea 
Muricauda aquimarina Flavobacteria; Gram (-); 0.2–0.5 mm x 2.5–6.0 mm; rod shape; 
golden yellow colony; aerobic; 1-10% NaCl; isolated from Korea 
Phyllobacterium sp. Alphaproteobacteria; Gram (-); rod shape; transparent colony; 
aerobic; 1% NaCl 
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Table 11. Antimalarial activities of metabolites in the extracts of different bacterial strains living 
in association of R. reptotaenium culture. 
Types of  
extracts 
Baterial strains 
P. falciparum D6 
(W2) IC50 (ng/mL) 
VERO IC50 
P. falciparum 
D6 (W2)  SI 
Supernatant 
extract 
Labrenzia alexandrii  28000 (37000) >47600 1.7 (1.2) 
Labrenzia aggregata  >47600 >47600 1 
Kordiimonas sp. >47600 >47600 1 
Muricauda sp. 44000 (46000) >47600 >1 
Stappia sp. >47600 >47600 1 
Phyllobacterium sp. >47600 >47600 1 
6 bacteria growing together >47600 >47600 1 
Biomass  
extracts 
Labrenzia alexandrii  >47600 >47600 1 
Labrenzia aggregata  >47600 >47600 1 
Kordiimonas sp. >47600 >47600 1 
Muricauda sp. >47600 >47600 1 
Stappia sp. >47600 >47600 1 
Phyllobacterium sp. >47600 >47600 1 
6 bacteria growing together >47600 >47600 1 
 
  
 64 
Table 12. Antimalarial activities of different parts of the active fractions (supernatant-acetone 
100%) 
Parts 
P. falciparum D6 (W2) 
IC50 
(ng/mL) 
VERO IC50 
(ng/mL) 
P. falciparum D6 (W2) SI 
 
0-2.5 min >1190 >1190 1 
2.5-4.5 min <4.9 587.8 120 
4.5-9.0 min 156.1 (108.6) >1190 >7.6 (>11) 
9.0-12.0 min >1190 >1190 1 
Combination 25 (13.8) >1190 >47.6 (>86.5) 
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Table 13. The relative abundance (%) of major bacterial phyla and subphyla in R. reptotaenium 
2 weeks-old and 8 weeks-old culture. 
 % composition of the whole community 
 2 weeks 8 weeks 
Bacteroidetes 13.2 17.8 
Rhodothermi 7.8 9.1 
Saprospirae 0.9 3.7 
Cytophagia 4.0 3.4 
Flavobacteriia 0.6 1.6 
Cyanobacteria 7.6 4.1 
Oscillatoriophycideae 7.6 4.1 
Planctomycetes 12.7 15.2 
Phycisphaerae 3.5 2.1 
Planctomycetia 9.2 13.1 
Proteobacteria 60.4 55.0 
Alphaproteobacteria 58.6 52.9 
Betaproteobacteria 0.1 0.1 
Gammaproteobacteria 1.6 2.1 
Other 6.1 7.9 
Total 100 100 
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